Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) have earned a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $24.64.
A number of research firms have recently commented on NEO. Raymond James lowered their price target on NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, April 18th. Benchmark lowered their target price on NeoGenomics from $26.00 to $16.00 in a report on Tuesday, March 29th. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. StockNews.com raised NeoGenomics to a “sell” rating in a report on Thursday, May 12th. Finally, Morgan Stanley lowered their target price on NeoGenomics from $29.00 to $27.00 and set an “equal weight” rating for the company in a report on Tuesday, April 12th.
Shares of NeoGenomics stock traded up $0.09 during trading on Friday, reaching $8.80. 83,433 shares of the company’s stock were exchanged, compared to its average volume of 2,380,564. The company has a debt-to-equity ratio of 0.50, a quick ratio of 7.64 and a current ratio of 7.93. NeoGenomics has a 1-year low of $7.26 and a 1-year high of $54.74. The company has a market cap of $1.10 billion, a P/E ratio of -27.28 and a beta of 0.86. The firm’s 50-day moving average price is $12.31 and its 200 day moving average price is $23.24.
NeoGenomics (NASDAQ:NEO – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. NeoGenomics had a negative return on equity of 6.62% and a negative net margin of 7.33%. The company had revenue of $117.17 million during the quarter, compared to analysts’ expectations of $116.44 million. During the same quarter in the previous year, the firm earned ($0.06) EPS. NeoGenomics’s revenue was up 1.4% on a year-over-year basis. As a group, equities research analysts predict that NeoGenomics will post -0.98 EPS for the current year.
In related news, CFO William Bonello sold 3,209 shares of the company’s stock in a transaction dated Monday, March 7th. The stock was sold at an average price of $18.29, for a total transaction of $58,692.61. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in NeoGenomics by 11.0% in the third quarter. Barclays PLC now owns 137,913 shares of the medical research company’s stock worth $6,652,000 after acquiring an additional 13,691 shares in the last quarter. CIBC Asset Management Inc bought a new position in NeoGenomics in the third quarter worth approximately $233,000. Teacher Retirement System of Texas boosted its holdings in NeoGenomics by 36.6% in the third quarter. Teacher Retirement System of Texas now owns 18,417 shares of the medical research company’s stock worth $888,000 after acquiring an additional 4,938 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in NeoGenomics by 29.4% in the third quarter. O Shaughnessy Asset Management LLC now owns 7,288 shares of the medical research company’s stock worth $352,000 after acquiring an additional 1,657 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in NeoGenomics by 8.0% in the third quarter. California Public Employees Retirement System now owns 249,043 shares of the medical research company’s stock worth $12,014,000 after acquiring an additional 18,348 shares in the last quarter. Institutional investors own 95.03% of the company’s stock.
About NeoGenomics (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Featured Articles
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
This news is republished from another source. You can check the original article here
Be the first to comment